BiotechTube

Glecaprevir-pibrentasvir

ApprovedUNKNOWN
2 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hepatitis C

Conditions

Hepatitis C, Addict Heroin

Trial Timeline

Jan 15, 2018 → Mar 1, 2019

NCT ID
NCT03364725

About Glecaprevir-pibrentasvir

Glecaprevir-pibrentasvir is a approved stage product being developed by AbbVie for Hepatitis C. The current trial status is unknown. This product is registered under clinical trial identifier NCT03364725. Target conditions include Hepatitis C, Addict Heroin.

What happened to similar drugs?

20 of 20 similar drugs in Hepatitis C were approved

Approved (20) Terminated (8) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Pegylated Interferon + RibavirinAstellas PharmaApproved
✅ABT450r-ABT267-ABT333 +/- RibavirinAbbVieApproved
✅PTV/r/OBV/DSVAbbVieApproved
✅SOF/LDV (sofosbuvir/ledipasvir) + PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only) + EBR/GZR (elbasvir/grazoprevir) + RibavirinAbbVieApproved
✅OBV/PTV/r and DSV + Placebo to match OBV/PTV/r and DSVAbbVieApproved
✅Glecaprevir and PibrentasvirAbbVieApproved

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03364725ApprovedUNKNOWN

Competing Products

20 competing products in Hepatitis C

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
43
peginterferon alfa-2a + rivavirinChugai PharmaceuticalPhase 3
40
SOF + COPEChugai PharmaceuticalPre-clinical
26
Colesevelam HclDaiichi SankyoPhase 2
35
ASP9831 + PlaceboAstellas PharmaPhase 2
35
FK788Astellas PharmaPhase 2
35
MK-2248MerckPhase 1
29
Interferon alfacon-1Astellas PharmaPhase 3
40
Pegylated Interferon + RibavirinAstellas PharmaApproved
35
Tacrolimus + steroids, monoclonal anti-IL2R antibodyAstellas PharmaPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir + MethadoneShionogiPhase 1
29
Clevudine + AdefovirEisaiPhase 3
40